Sanofi Sa Stock Working Capital

SAN Stock  EUR 92.10  0.21  0.23%   
Sanofi SA fundamentals help investors to digest information that contributes to Sanofi SA's financial success or failures. It also enables traders to predict the movement of Sanofi Stock. The fundamental analysis module provides a way to measure Sanofi SA's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Sanofi SA stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Sanofi SA Company Working Capital Analysis

Sanofi SA's Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .

Working Capital

 = 

Current Assets

-

Current Liabilities

More About Working Capital | All Equity Analysis
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
Competition

Based on the company's disclosures, Sanofi SA has a Working Capital of 0.0. This is 100.0% lower than that of the Healthcare sector and about the same as Drug Manufacturers—General (which currently averages 0.0) industry. The working capital for all France stocks is 100.0% higher than that of the company.

Sanofi Working Capital Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sanofi SA's direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Sanofi SA could also be used in its relative valuation, which is a method of valuing Sanofi SA by comparing valuation metrics of similar companies.
Sanofi SA is currently under evaluation in working capital category among its peers.

Sanofi Fundamentals

About Sanofi SA Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Sanofi SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sanofi SA using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sanofi SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in Sanofi Stock

Sanofi SA financial ratios help investors to determine whether Sanofi Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Sanofi with respect to the benefits of owning Sanofi SA security.